









Mercado
/
Acciones
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

190.440USD

-1.250-0.65%

Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min

3.74BCap. mercado

79.51P/E TTM



Ligand Pharmaceuticals Inc

190.440

-1.250-0.65%

Descripción general Finanzas Análisis Compañía

Descripción general

Finanzas

Análisis

Compañía

Más Datos de Ligand Pharmaceuticals Inc Compañía

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Información de Ligand Pharmaceuticals Inc



Símbolo de cotizaciónLGND

Nombre de la empresaLigand Pharmaceuticals Inc

Fecha de salida a bolsaNov 18, 1992

Director ejecutivoDavis (Todd C)

Número de empleados68

Tipo de seguridadOrdinary Share

Fin del año fiscalNov 18

Dirección555 Heritage Drive, Suite 200

CiudadJUPITER

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal33458

Teléfono18585507500

Sitio Webhttps://www.ligand.com/

Símbolo de cotizaciónLGND

Fecha de salida a bolsaNov 18, 1992

Director ejecutivoDavis (Todd C)

Ejecutivos de Ligand Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Jason M. Aryeh

Independent Director

129.19K

+2034.00%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+1209.00%

Mr. Andrew Reardon

Chief Legal Officer

15.72K

-1325.00%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

8.84K

-1277.00%

Mr. Jason Haas

Independent Director

6.86K

+1209.00%

Dr. Martine Zimmermann, Pharm.D.

Independent Director

4.17K

-115.00%

Mr. Todd C. Davis

Chief Executive Officer, Director

Dr. John L. Lamattina, Ph.D.

Independent Director

Ms. Melanie J. Herman

Investor Relations

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Jason M. Aryeh

Independent Director

129.19K

+2034.00%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+1209.00%

Mr. Andrew Reardon

Chief Legal Officer

15.72K

-1325.00%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

8.84K

-1277.00%

Mr. Jason Haas

Independent Director

6.86K

+1209.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Contract Revenue- Other

58.20M

50.41%

Kyprolis

11.62M

10.06%

Captisol

10.67M

9.24%

Filspari

9.08M

7.86%

Qarziba

5.98M

5.18%

Otro

19.91M

17.25%

La empresa aún no ha revelado los datos relevantes.

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Contract Revenue- Other

58.20M

50.41%

Kyprolis

11.62M

10.06%

Captisol

10.67M

9.24%

Filspari

9.08M

7.86%

Qarziba

5.98M

5.18%

Otro

19.91M

17.25%

Estadísticas de accionistas

Actualizado: vie., 30 de ene

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

13.35%

The Vanguard Group, Inc.

10.51%

Janus Henderson Investors

5.30%

Nomura Investment Management Business Trust

3.82%

State Street Investment Management (US)

3.81%

Otro

63.22%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

13.35%

The Vanguard Group, Inc.

10.51%

Janus Henderson Investors

5.30%

Nomura Investment Management Business Trust

3.82%

State Street Investment Management (US)

3.81%

Otro

63.22%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

57.90%

Investment Advisor/Hedge Fund

38.29%

Research Firm

3.68%

Individual Investor

2.27%

Bank and Trust

1.68%

Pension Fund

1.63%

Hedge Fund

0.72%

Family Office

0.16%

Sovereign Wealth Fund

0.10%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

591

20.54M

104.36%

-316.11K

2025Q3

541

20.07M

102.40%

-232.93K

2025Q2

535

19.71M

102.13%

-738.05K

2025Q1

554

19.82M

102.82%

-711.89K

2024Q4

546

19.28M

100.16%

-1.51M

2024Q3

543

19.17M

104.83%

-583.22K

2024Q2

527

18.31M

101.74%

-865.78K

2024Q1

520

17.60M

99.35%

-393.03K

2023Q4

527

16.97M

97.29%

-861.76K

2023Q3

515

17.24M

99.38%

-910.17K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

2.63M

13.35%

-27.96K

-1.05%

Sep 30, 2025

The Vanguard Group, Inc.

2.07M

10.53%

-13.09K

-0.63%

Sep 30, 2025

Janus Henderson Investors

1.04M

5.3%

-18.36K

-1.73%

Sep 30, 2025

Nomura Investment Management Business Trust

751.79K

3.82%

-174.77K

-18.86%

Sep 30, 2025

State Street Investment Management (US)

749.36K

3.81%

-394.00

-0.05%

Sep 30, 2025

Chicago Capital, LLC

568.61K

2.89%

-3.21K

-0.56%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

523.91K

2.66%

-180.61K

-25.64%

Sep 30, 2025

MFS Investment Management

541.85K

2.75%

+202.10K

+59.49%

Sep 30, 2025

Stephens Investment Management Group, LLC

554.54K

2.82%

-50.27K

-8.31%

Sep 30, 2025

Congress Asset Management Company, LLP

667.31K

3.39%

+19.37K

+2.99%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Franklin Genomic Advancements ETF

4.21%

Invesco Pharmaceuticals ETF

3.2%

State Street SPDR S&P Pharmaceuticals ETF

3.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.74%

Virtus LifeSci Biotech Products ETF

2.67%

Invesco S&P SmallCap Health Care ETF

2.3%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.73%

Invesco Dorsey Wright Healthcare Momentum ETF

1.64%

iShares U.S. Pharmaceuticals ETF

1.38%

First Trust Multi-Manager Small Cap Opportunities ETF

1.09%

Franklin Genomic Advancements ETF

Proporción4.21%

Invesco Pharmaceuticals ETF

Proporción3.2%

State Street SPDR S&P Pharmaceuticals ETF

Proporción3.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción2.74%

Virtus LifeSci Biotech Products ETF

Proporción2.67%

Invesco S&P SmallCap Health Care ETF

Proporción2.3%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporción1.73%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporción1.64%

iShares U.S. Pharmaceuticals ETF

Proporción1.38%

First Trust Multi-Manager Small Cap Opportunities ETF

Proporción1.09%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

